Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W H Yee

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|September 2, 1998
Blind to the danger?W H Yee
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|March 1, 1990
Accidental strangulation by window-blind cordsW H Yee
Physiological Chemistry and Physics|January 1, 1973
A note on the effect of electromagnetic field on enzymic substratesR L Sherman, S T Siebert, W H Yee
Journal of Perinatology : Official Journal of the California Perinatal Association|November 21, 2008
Relationship between oxygen saturation and the mode of oxygen delivery used in newborn resuscitationY Rabi, S Y Chen, W H Yee, et al.
Cell Cycle (Georgetown, Tex.)|July 24, 2009
The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicinMarcus M Schittenhelm, Kerstin M Kampa, Kevin W H Yee, et al.
Journal of Perinatology : Official Journal of the California Perinatal Association|October 11, 2001
Evaluation of the effectiveness of the standardized neonatal resuscitation programN Singhal, D D McMillan, W H Yee, et al.
Blood|August 12, 2004
Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cellsKevin W H Yee, Marcus Schittenhelm, Anne-Marie O'Farrell, et al.
Blood|August 12, 2004
Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970Amie S Corbin, Ian J Griswold, Paul La Rosée, et al.
Blood|September 28, 2002
SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinaseKevin W H Yee, Anne Marie O'Farrell, Beverly D Smolich, et al.
Leukemia|September 23, 2006
FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248)M M Schittenhelm, K W H Yee, J W Tyner, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|September 2, 1998
Blind to the danger?W H Yee
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|March 1, 1990
Accidental strangulation by window-blind cordsW H Yee
Physiological Chemistry and Physics|January 1, 1973
A note on the effect of electromagnetic field on enzymic substratesR L Sherman, S T Siebert, W H Yee
Journal of Perinatology : Official Journal of the California Perinatal Association|November 21, 2008
Relationship between oxygen saturation and the mode of oxygen delivery used in newborn resuscitationY Rabi, S Y Chen, W H Yee, et al.
Cell Cycle (Georgetown, Tex.)|July 24, 2009
The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicinMarcus M Schittenhelm, Kerstin M Kampa, Kevin W H Yee, et al.
Journal of Perinatology : Official Journal of the California Perinatal Association|October 11, 2001
Evaluation of the effectiveness of the standardized neonatal resuscitation programN Singhal, D D McMillan, W H Yee, et al.
Blood|August 12, 2004
Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cellsKevin W H Yee, Marcus Schittenhelm, Anne-Marie O'Farrell, et al.
Blood|August 12, 2004
Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970Amie S Corbin, Ian J Griswold, Paul La Rosée, et al.
Blood|September 28, 2002
SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinaseKevin W H Yee, Anne Marie O'Farrell, Beverly D Smolich, et al.
Leukemia|September 23, 2006
FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248)M M Schittenhelm, K W H Yee, J W Tyner, et al.
Pageof 2